Last reviewed · How we verify
Topical organogel with nitroglycerin
Nitroglycerin releases nitric oxide to dilate blood vessels and improve blood flow when applied topically as an organogel formulation.
Nitroglycerin releases nitric oxide to dilate blood vessels and improve blood flow when applied topically as an organogel formulation. Used for Topical vasodilation for improved blood flow (specific indication under investigation in phase 3).
At a glance
| Generic name | Topical organogel with nitroglycerin |
|---|---|
| Sponsor | MediQuest Therapeutics |
| Drug class | Nitrate vasodilator |
| Target | Guanylate cyclase (via nitric oxide) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Nitroglycerin is a nitrate vasodilator that is bioconverted to nitric oxide, which activates guanylate cyclase and increases cGMP levels in vascular smooth muscle, leading to vasodilation. The organogel formulation provides sustained topical delivery of nitroglycerin to affected tissues, improving local blood perfusion. This mechanism is used to treat conditions characterized by reduced blood flow or vascular dysfunction.
Approved indications
- Topical vasodilation for improved blood flow (specific indication under investigation in phase 3)
Common side effects
- Headache
- Hypotension
- Flushing
- Local skin irritation
Key clinical trials
- Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon (PHASE3)
- Lab Study of MQX-503 in Treatment of Raynaud's (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical organogel with nitroglycerin CI brief — competitive landscape report
- Topical organogel with nitroglycerin updates RSS · CI watch RSS
- MediQuest Therapeutics portfolio CI